Brain Dopamine Function in Human Obesity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03648892|
Recruitment Status : Recruiting
First Posted : August 28, 2018
Last Update Posted : July 16, 2019
Dopamine is a natural chemical in the brain that may influence eating behavior and physical activity. Researchers want to measure the brain s dopamine activity and understand how it differs in people with obesity.
To better understand how brain function, particularly dopamine activity, relates to body weight and eating behavior.
Individuals may be able to participate if they:
Have a BMI of at least 18.5 kg/m2
Are weight-stable and generally healthy
Are between ages 18-45 years
Have normal blood pressure
Are not using illegal drugs (based on urine drug screen)
Are not following a special diet
Do not have metal implants
Participants will be screened with:
- Medical history
- Physical exam
- Questionnaires and an interview to see if it is safe to have a PET/MRI scan
- Fasting blood and urine tests
- Participants will eat a special diet given to them for the 5 days before their inpatient visit.
Participants will have a 5-day inpatient visit. Some days include blood and urine tests. Each day includes surveys and tests to measure habits and likes/dis-likes. A sample schedule may be:
Day 1: Participants will wear a monitor that uses a needle below the skin to measure glucose. Their body fat will be measured with low-dose x-rays
Day 2: Participants will have a PET scan. They will lie on a table that slides in and out of a donut-shaped scanner. They will be injected with a small amount of a radioactive substance and wear a cap on their head.
Day 3: Participants will have an MRI. They will lie on a table that slides in and out of a scanner.
Day 4: Participants will have another PET scan. This time, they will drink a milk shake during a break from the scanner. Then, they will go back inside the scanner for the end of their scan.
Day 5: Participants will wear a hood for up to 40 minutes to measure their breathing. They will also drink special water and collect samples of their urine to measure the rate they burn energy.
For 12 months after the visit, participants will track their weight and physical activity daily using a special scale and activity monitor. A few times over the year, the study team will send participants special activity monitors to use for 7 days at a time.
Participants will have an in-person 1-day follow-up visit. This includes most tests except for PET scanning....
|Condition or disease|
|Obesity Healthy Volunteers Overweight|
Evidence from neuroimaging studies indicates that aberrant functionality in brain regions that support reward processing and habit formation may be related to an individual's eating behavior and obesity propensity. In particular, our previous research found that increased dopamine D2 receptor binding potential (D2BP) in the dorsal and lateral striatum was positively related to opportunistic eating behaviors, body fat, and body mass index (BMI). However, our findings were contrary to highly-cited previous reports of D2BP correlating with BMI in the opposite direction. The primary aim of this study is to elucidate the reasons for the conflicting results that used somewhat different methodologies.
Specifically, our previous study used positron emission tomography (PET) to measure D2BP using the dopamine D2 receptor antagonist radioligand [18F]fallypride following a period of dietary stabilization and 3 hours after a standardized breakfast. Reports finding correlations between D2BP and BMI in the opposite direction have typically investigated subjects with higher BMI using the D2 receptor antagonist radioligand [11C]raclopride. Furthermore, previous studies were typically conducted in the fasted state, but the subjects prior food intake was not wellcontrolled. The present study will attempt to resolve the controversy by measuring D2BP using both [18F]fallypride and [11C]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from [18F]fallypride and [11C]raclopride.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Brain Dopamine Function in Human Obesity|
|Actual Study Start Date :||September 21, 2018|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||December 31, 2021|
Healthy Volunteers with a BMI greater than or equal to 18.5 kg/m^2 and less than 25 kg/m^2
Healthy Volunteers with a BMI greater than or equal to 25 kg/m^2 and less than 35 kg/m^2
Healthy Volunteers with a BMI greater than or equal to 35 kg/m^2
- To determine if D2BP is related to BMI and whether there is a linear or quadratic relationship. [ Time Frame: Ongoing ]
- To determine correlations between D2BP, as measured by [18F]fallypride and [11C]raclopride time-activity curves. [ Time Frame: Ongoing ]
- To determine the effect of palatable meal consumption on D2BP in individuals with a wide BMI range. Binding potential estimates will be estimated within subjects using [11C]raclopride [ Time Frame: Ongoing ]
- Investigate the associations between brain dopamine D2BP and neural bases of food perception and preference [ Time Frame: Ongoing ]
- Investigate the metabolic and endocrine correlates of brain dopamine D2BP and neural bases of food perception and preference. [ Time Frame: Ongoing ]
- Investigate the behavioral correlates of brain dopamine D2BP such as free-living physical activity, ad libitum meal consumption, and body weight changes over a one year period. [ Time Frame: Ongoing ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03648892
|Contact: Irene T Rozga, R.N.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Kevin Hall, Ph.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|